Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

Completed · Phase 2

Conditions studied: Acute Myeloid Leukemia

In brief

The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).

Key facts

Study ID

NCT00358644

Run by

Eisai Inc.

People needed

55

Starts

2005-03-01

Expected to finish

2008-12-01

Last updated by the study team

2013-05-20

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of AML or transformed from myelodysplastic syndrome (MDS) within 2 weeks of study enrollment.
• Ineligible to receive intensive chemotherapy for their disease.
• Have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatment-related toxicities.

You may not qualify if…

• Received previous treatment for AML.
• Previously received Vidaza.
• Received any other investigational agents within 30 days of first dose of study drug.
• Uncontrolled intercurrent illness.
• Had radiotherapy within 14 days prior to study enrollment.

Where it is running

• Study site — Duarte, California, United States
• Study site — Los Angeles, California, United States
• Study site — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.